# Dalbavancin Therapy for Infective Endocarditis

> **NCT07699211** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Stefan Hagel** · enrollment: 184 (estimated)

## Conditions studied

- Endocarditis Infective
- Endocarditis, Bacterial

## Interventions

- **DRUG:** Dalbavancin administration
- **DRUG:** Standard of Care (Investigator Choice)

## Key facts

- **NCT ID:** NCT07699211
- **Lead sponsor:** Stefan Hagel
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-09
- **Final completion:** 2029-12
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699211, "Dalbavancin Therapy for Infective Endocarditis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*